5th International VPM Days
“Translational Medicine: Current Concepts and Beyond” 1.-2. September 2011 im TWINCORE in Hannover

Wie die Jahre zuvor freuen wir uns, dass herausragende Redner unserer Einladung gefolgt sind und ihre Erfahrung mit uns teilten. Die Vorträge sind unter den jeweiligen Programmpunkten online verfügbar.

September 1st, 2011
Key Note Lecture:
13.40 – 14.10 Prof. Dr. John Oxford (Retroscreen Virology Ltd.)
“Challenges in Molecular Vaccine Research”

Session 1: Research

14.10 – 14.30 PD Dr. Zoe Waibler (PEI)
„From Bedside to Bench: TGN1412”
14.30 – 14.50 Prof. Dr. Camille Locht (Institut Pasteur de Lille)
"TB or not TB, the Concept of Latency and Vaccine Development against Tuberculosis"
14.50– 15.10 Dr. Hansjörg Hauser (HZI)
„German Center for Infection Research (DZIF)”

Session 2: Legal / IP & Finance

16.00 – 16.20 Dr. Jürgen Meier (Vossius & Partner)
“Supplementary Protection Certificates in Medicine - Prolongation of Patent Protection Term”
16.20 – 16.40 Thieß Gert Matzke (Ascenion GmbH)
"Equitable Licensing - A Challenge for Technology Transfer"
16.40 – 17.00 Dr. Christian Stein (Ascenion GmbH)
„Spinnovator - Public-Private Partnership to finance the gap”

September 2nd, 2011
Session 3: Regulatory

08.30 – 08.50 Dr. Thomas Hinz (Paul-Ehrlich-Institut)
“Development Stage of Therapeutic Vaccines: The Regulator’s View”
08.50 – 09.10 Dr. Ute Krahl (BioRegConsultancy)
„Future Role of Biomarkers and Personalized Medicine in Development of New Medicines”
09.10 – 09.30 Prof. Dr. Ulrich Kalinke (TWINCORE GmbH)
"How vaccines work: New developments in adjuvant research"

Session 4: GMP / CMO

10.00 – 10.20 Dr. Rainer Lichtenberger (CEVEC Pharmaceuticals GmbH)
„Cevec Pharmaceuticals GmbH – Utilizing the Unique CAP-Cell Line to Provide Vaccines and Complex Human Proteins”
10.20 – 10.40 Dr. Kai Lipinski (Vibalogics GmbH)
"Implementation of Disposable Technologies for the Manufacture of Biologicals - Live Virus and Microbial Case Studies"
10.40 – 11.00 Dr. Klaus Kühlcke (EUFETS AG)
„Product development for a gene modified cellular cancer immunotherapy”

Session 5: Translational Medicine

11.30 – 11.50 Dr. Odile Leroy (EVI/TRANSVAC)
“How to strenghten the vaccine infrastructure in Europe? The role of PDPs and EC”
11.50 – 12.10 Jelle Thole (TBVI)
“Research and Development of new TB vaccines”
12.10 – 12.30 Prof. Dr. Norbert Krug (Fraunhofer ITEM)
„The concept of the new Clinical Research Center (CRC) Hannover”
12.30 – 12.50 Dr. Marc W. Hentz (TRAIN)
„Novel translational infrastructures in academia“

For additional information please contact:

Inge Jacobi
Conference Manager
Tel: +49 511 169908-11
Fax: +49 511 169908-29
info@vakzine-manager.de